BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
320.41
-9.74 (-2.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close330.15
Open323.06
Bid318.76 x 800
Ask320.73 x 900
Day's Range318.52 - 327.00
52 Week Range249.17 - 388.67
Volume1,772,526
Avg. Volume1,355,929
Market Cap64.544B
Beta (3Y Monthly)1.53
PE Ratio (TTM)22.75
EPS (TTM)14.08
Earnings DateOct 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est392.16
Trade prices are not sourced from all markets
  • Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
    Zacks18 hours ago

    Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?

    On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist20 hours ago

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Biogen: Revenue Growth Is Expected in Q3
    Market Realist22 hours ago

    Biogen: Revenue Growth Is Expected in Q3

    As we discussed in the previous part, analysts expect Biogen’s (BIIB) revenues to increase 8.3% to $3.33 billion during the third quarter. Biogen’s product portfolio includes multiple sclerosis products, spinal muscular atrophy products, biosimilars, and other products. Biogen’s portfolio also includes Anti-CD20 therapeutic programs.

  • Analyzing Biogen before Its Third-Quarter Earnings
    Market Realist23 hours ago

    Analyzing Biogen before Its Third-Quarter Earnings

    Biogen (BIIB), a leading biotechnology company, is scheduled to release its third-quarter earnings on October 23. Analysts expect the adjusted EPS to be $6.78 on revenues of $3.33 billion during the third quarter.

  • Alkermes Boasts Strong Portfolio and Impressive Pipeline
    Zacksyesterday

    Alkermes Boasts Strong Portfolio and Impressive Pipeline

    Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

  • CNBCyesterday

    Stocks making the biggest move premarket: PG, HON, F, VFC, HOG AMZN & more

    Procter & Gamble PG – The consumer products giant reported adjusted quarterly profit of $1.12 per share , exceeding estimates by 3 cents a share. Revenue also came in above Street forecasts and the company posted organic sales growth of 4 percent for its fiscal first quarter. Honeywell HON – Honeywell earned an adjusted $2.03 per share for the third quarter , 4 cents a share above estimates.

  • GlobeNewswire2 days ago

    Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

    EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27).

  • MIT researchers among winners of prestigious Breakthrough Prize
    American City Business Journals3 days ago

    MIT researchers among winners of prestigious Breakthrough Prize

    The honorees include several MIT researchers and the developers of a drug sold by Cambridge-based Biogen.

  • Reuters3 days ago

    Samsung launches third rival to AbbVie's Humira drug in EU

    LONDON (Reuters) - South Korea's Samsung Bioepis and its partner Biogen (BIIB.O) have launched a third rival to AbbVie's (ABBV.N) blockbuster medicine Humira in Europe, ramping up competition for a slice ...

  • Reuters3 days ago

    Samsung launches third rival to AbbVie's Humira drug in EU

    South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up competition for a slice of the world's top-selling prescription drug's sales. A fourth so-called biosimilar copy of Humira is expected soon from Mylan . The primary European patent on Humira expired on Oct. 16, opening the door to cheaper near-identical copies for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

  • Business Wire3 days ago

    Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market

    CAMBRIDGE, Mass. & INCHEON, Korea-- -- IMRALDI TM , a biosimilar referencing HUMIRA ® i , is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialized by Biogen across Europe, following BENEPALI TM and FLIXABI TM Biogen and Samsung Bioepis were the first in Europe to receive approvals for biosimilars referencing the three most prescribed anti-TNF medicines in Europe. Biogen and ...

  • GlobeNewswire3 days ago

    IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

    IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product In 2017 Biogen became the first company in Europe with.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realist4 days ago

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realist5 days ago

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realist5 days ago

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • Analyzing Sarepta’s Product Pipeline
    Market Realist5 days ago

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene. 

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realist8 days ago

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

  • Investor Insights: Teva Pharmaceutical’s Valuation Multiples
    Market Realist9 days ago

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

  • The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC

    The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist9 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • GlobeNewswire9 days ago

    Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

    Through its research initiatives, Biogen Inc. (BIIB) aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with real-world evidence to help inform treatment decisions. Data show serum neurofilament light (sNfL) is a potential biomarker of disease activity and treatment response, and results from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) support the use of technology to broadly monitor for clinically important outcomes, including cognitive changes.

  • Top Analyst Reports for Altria, U.S. Bancorp & Biogen
    Zacks10 days ago

    Top Analyst Reports for Altria, U.S. Bancorp & Biogen

    Top Analyst Reports for Altria, U.S. Bancorp & Biogen

  • Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
    Zacks10 days ago

    Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status

    Data presentations by leading sector players take center stage this week.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist10 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • A Financial Overview of Neurocrine Biosciences in October
    Market Realist11 days ago

    A Financial Overview of Neurocrine Biosciences in October

    Neurocrine Biosciences’ (NBIX) revenues grew from $6.3 million in the second quarter of 2017 to $96.9 million in the second quarter. The company reported net revenues of $168.0 million in the first half of this year, which grew from $6.3 million in the first half of 2017. Wall Street analysts expect Neurocrine Biosciences to generate revenues of $151.8 million in the third quarter.